NO20084744L - Trisubstituerte 1,2,4-triazoler - Google Patents

Trisubstituerte 1,2,4-triazoler

Info

Publication number
NO20084744L
NO20084744L NO20084744A NO20084744A NO20084744L NO 20084744 L NO20084744 L NO 20084744L NO 20084744 A NO20084744 A NO 20084744A NO 20084744 A NO20084744 A NO 20084744A NO 20084744 L NO20084744 L NO 20084744L
Authority
NO
Norway
Prior art keywords
positive allosteric
allosteric modulators
trisubstituted
triazoles
relates
Prior art date
Application number
NO20084744A
Other languages
English (en)
Other versions
NO342797B1 (no
Inventor
Marcel Frans Leopold De Bruyn
Anne Simone Josephine Lesage
Yves Emiel Maria Van Roosbroeck
Gregor James Macdonald
Frans Alfons Maria Van Keybus
Johannes Wilhelmus Joh Thuring
Wei Zhuang
Theodorus Dinklo
James Edward Stewart Duffy
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of NO20084744L publication Critical patent/NO20084744L/no
Publication of NO342797B1 publication Critical patent/NO342797B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/14—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Den foreliggende oppfinnelsen angår 3-anilin-5-aryltriazolderivater og analoger eller farmasøytisk akseptable salter derav, metoder for å fremstille dem, farmasøytiske sammensetninger inneholdende dem og deres anvendelse i terapi, ifølge formel (I). Oppfinnelsen angår spesielt positive allosteriske modulatorer av nikotinacetylkolinreseptorer, slike positive allosteriske modulatorer har evnen til å øke effektiviteten av nikotinreseptoragonister.
NO20084744A 2006-04-19 2008-11-10 Trisubstituerte 1,2,4-triazoler NO342797B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06112754 2006-04-19
PCT/EP2007/053829 WO2007118903A1 (en) 2006-04-19 2007-04-19 Trisubstituted 1,2,4-triazoles

Publications (2)

Publication Number Publication Date
NO20084744L true NO20084744L (no) 2008-11-10
NO342797B1 NO342797B1 (no) 2018-08-06

Family

ID=37814207

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20084744A NO342797B1 (no) 2006-04-19 2008-11-10 Trisubstituerte 1,2,4-triazoler

Country Status (22)

Country Link
US (1) US8143419B2 (no)
EP (1) EP2010516B1 (no)
JP (1) JP5439169B2 (no)
KR (1) KR101465413B1 (no)
CN (1) CN101472911B (no)
AR (1) AR060537A1 (no)
AU (1) AU2007239498B2 (no)
BR (1) BRPI0710819A2 (no)
CA (1) CA2648157C (no)
EA (1) EA016289B1 (no)
ES (1) ES2501946T3 (no)
HK (1) HK1135375A1 (no)
IL (1) IL194744A (no)
JO (1) JO3019B1 (no)
MX (1) MX2008013457A (no)
MY (1) MY147212A (no)
NO (1) NO342797B1 (no)
NZ (1) NZ572468A (no)
TW (1) TWI408132B (no)
UA (1) UA95281C2 (no)
WO (1) WO2007118903A1 (no)
ZA (1) ZA200808916B (no)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3019B1 (ar) 2006-04-19 2016-09-05 Janssen Pharmaceutica Nv ثلاثي مستبدل 4،2،1-ثلاثي زولات
US20100234349A1 (en) * 2006-09-04 2010-09-16 Olsen Gunnar M Pharmaceutical combinations of a nicotine receptor modulator and a cognitive enhancer
RU2474579C2 (ru) * 2007-10-18 2013-02-10 Янссен Фармацевтика Нв Тризамещенные 1,2,4-триазолы
JO2784B1 (en) * 2007-10-18 2014-03-15 شركة جانسين فارماسوتيكا ان. في 5,3,1 - Triazole substitute derivative
AU2009226988B2 (en) 2008-03-19 2013-05-23 Janssen Pharmaceutica Nv Trisubstituted 1, 2, 4 -triazoles as nicotinic acetylcholine receptor modulators
JP5486591B2 (ja) * 2008-05-09 2014-05-07 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ アセチルコリン受容体モジュレーターとしての三置換ピラゾール
CN102574832B (zh) * 2009-09-17 2014-09-24 詹森药业有限公司 取代的n-苯基-1-(4-吡啶基)-1h-吡唑-3-胺
JO3078B1 (ar) * 2009-11-27 2017-03-15 Janssen Pharmaceutica Nv مورفولينوثيازولات بصفتها منظمات الوستيرية نوع الفا 7 موجبة
WO2012104782A1 (en) 2011-02-03 2012-08-09 Lupin Limited Pyrrole derivatives used as modulators of alpha7 nachr
PL2678327T3 (pl) 2011-02-23 2017-02-28 Lupin Limited Pochodne heteroarylowe jako modulatory Alfa 7 NACHR
WO2012113850A2 (en) 2011-02-25 2012-08-30 Janssen Pharmaceutica Nv (PYRIDIN-4-YL)BENZYLAMIDES AS ALLOSTERIC MODULATORS OF ALPHA 7 nAChR
AU2012235779B2 (en) 2011-03-31 2017-03-02 Lupin Limited Pyrrole derivatives as nicotinic acetylcholine receptor modulators for use in the treatment of neurodegenerative disorders such as Alzheimer's and Parkinson's disease
EP2729455B1 (en) 2011-07-05 2016-09-14 Lupin Limited Biaryl derivatives as nachr modulators
IN2014MN01756A (no) 2012-03-06 2015-07-03 Lupin Ltd
EP2945936A1 (en) 2012-11-12 2015-11-25 Lupin Limited Thiazole derivatives as alpha 7 nachr modulators
WO2014111839A1 (en) 2013-01-16 2014-07-24 Lupin Limited Pyrrole derivatives as alpha 7 nachr modulators
WO2014141091A1 (en) 2013-03-13 2014-09-18 Lupin Limited Pyrrole derivatives as alpha 7 nachr modulators
TW201446243A (zh) 2013-06-03 2014-12-16 Lupin Ltd 4-(5-(4-氯苯基)-2-(2-環丙基乙醯基)-1,4-二甲基-1氫-吡咯-3-基)苯磺醯胺作為α7尼古丁乙醯膽鹼受體調節劑
EP3010899A1 (en) 2013-06-17 2016-04-27 Lupin Limited Pyrrole derivatives as alpha 7 nachr modulators
ES2796276T3 (es) * 2015-02-05 2020-11-26 Ab Science Compuestos con actividad antitumoral
CN110835336B (zh) * 2018-08-16 2022-10-04 中国药科大学 含氧杂环取代唑类化合物及其用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0248523B1 (en) 1986-05-07 1991-10-16 FISONS plc Pyrazoles
FR2792314B1 (fr) 1999-04-15 2001-06-01 Adir Nouveaux composes aminotriazoles, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
ATE257827T1 (de) * 1999-07-21 2004-01-15 Hoffmann La Roche Triazolderivate
FR2802530B1 (fr) 1999-12-17 2002-02-22 Sanofi Synthelabo Nouveaux derives amino substitues ramifies du 3-amino-1-phenyl-1h[1,2,4]triazole, procedes pour leur preparation et compositions pharmaceutiques les contenant
US7300933B2 (en) 2002-05-07 2007-11-27 Neurosearch A/S Diazabicyclic biaryl derivatives
BR0314183A (pt) * 2002-09-30 2005-08-09 Neurosearch As Derivados de 1,4-diazabicicloalcano, quaisquer de seus enanciÈmeros ou qualquer mistura de seus enaciÈmeros, ou um seu sal de adição farmaceuticamente aceitável ou um seu n-óxido, composição farmacêutica, uso do dito composto, de qualquer um de seus enanciÈmeros ou de qualquer mistura de seus enanciÈmeros, ou de um seu sal de adição farmaceuticamente aceitável, e, método de tratamento, prevenção ou alìvio de uma doença ou um distúrbio ou condição de um corpo animal vivo
WO2005004818A2 (en) * 2003-07-09 2005-01-20 Imclone Systems Incorporated Heterocyclic compounds and their use as anticancer agents
CA2532505A1 (en) 2003-07-24 2005-02-10 Pharmagene Laboratories Limited 5-ht2b receptor antagonists
FR2862647B1 (fr) 2003-11-25 2008-07-04 Aventis Pharma Sa Derives de pyrazolyle, procede de preparation et intermediaires de ce procede a titre de medicaments et de compositions pharmaceutiques les renfermant
WO2006064375A2 (en) 2004-12-16 2006-06-22 Ab Science Aminoaryl substituted five-membered ring heterocyclic compounds for the treatment of diseases
EP1926719B1 (en) 2005-09-13 2017-05-31 Janssen Pharmaceutica NV 2-aniline-4-aryl substituted thiazole derivatives
JO3019B1 (ar) 2006-04-19 2016-09-05 Janssen Pharmaceutica Nv ثلاثي مستبدل 4،2،1-ثلاثي زولات

Also Published As

Publication number Publication date
ZA200808916B (en) 2011-12-28
NO342797B1 (no) 2018-08-06
ES2501946T3 (es) 2014-10-02
WO2007118903A1 (en) 2007-10-25
JP2009534357A (ja) 2009-09-24
CA2648157C (en) 2012-04-03
AU2007239498B2 (en) 2012-08-23
UA95281C2 (en) 2011-07-25
IL194744A0 (en) 2009-08-03
EA200870448A1 (ru) 2009-02-27
MX2008013457A (es) 2008-10-30
EP2010516B1 (en) 2014-07-02
BRPI0710819A2 (pt) 2011-08-23
CA2648157A1 (en) 2007-10-25
JP5439169B2 (ja) 2014-03-12
NZ572468A (en) 2010-07-30
EP2010516A1 (en) 2009-01-07
TW200815396A (en) 2008-04-01
AR060537A1 (es) 2008-06-25
EA016289B1 (ru) 2012-03-30
IL194744A (en) 2016-10-31
US20090253691A1 (en) 2009-10-08
MY147212A (en) 2012-11-14
KR101465413B1 (ko) 2014-12-01
US8143419B2 (en) 2012-03-27
TWI408132B (zh) 2013-09-11
CN101472911A (zh) 2009-07-01
JO3019B1 (ar) 2016-09-05
CN101472911B (zh) 2014-07-02
AU2007239498A1 (en) 2007-10-25
HK1135375A1 (en) 2010-06-04
KR20090008335A (ko) 2009-01-21

Similar Documents

Publication Publication Date Title
NO20084744L (no) Trisubstituerte 1,2,4-triazoler
MY152486A (en) Trisubstituted 1,2,4 - triazoles as nicotinic acetylcholine receptor modulators
EA201071288A1 (ru) Тризамещенные пиразолы в качестве модуляторов рецепторов ацетилхолина
NO20070566L (no) Azin-karboksamider som antikreftmiddel
MY160728A (en) Morpholinothiazoles as alpha 7 positive allosteric modulators
WO2009155121A3 (en) Inhibitors of pi3 kinase
NO20071246L (no) Kinazolinonderivater og deres anvendelse som B-RAF-inhibitorer.
JO2784B1 (en) 5,3,1 - Triazole substitute derivative
NO20062004L (no) Forlenget frigjoring farmasoytiske blandinger omfattene aplindor og derivater derav
NO20084363L (no) 2-Substituerte 4-benzylftalazinonderivater som histamin H1- og H3-antagonister
NO20084489L (no) Azolopyrimidiner som inhibitorer av cannabinoid 1 aktivitet
NO20070336L (no) Indolderivater som histamin-reseptorantagonister
NO20076060L (no) Piperidin-4-yl-amidderivater og deres anvendelse som SST-reseptor subtype 5-antagonister
NO20084202L (no) 4-anilinoquinolin-3-carboksamider som CSF-1R kinase inhibitorer
TW200637874A (en) Peptides with neuropeptide-2 receptor (Y2R) agonist activity
ATE502017T1 (de) Pyrazolderivate als p2x7-modulatoren
ZA201002596B (en) 1,2,3-triazole derivatives for use as stearoyl-coa destaurase inhibitors
GEP20135744B (en) Quinuclidine carbonate derivatives and medicinal compositions containing the same
MX2009004745A (es) Derivados de 1,2,3-triazol como inhibidores del receptor sigma.
EA201270428A1 (ru) Замещенные n-фенил-1-(4-пиридинил)-1н-пиразол-3-амины
MX2010003923A (es) Formulacion farmaceutica de valsartan.
NO20076357L (no) Azabicykliske heterocykler som cannabinoid reseptor modulatorer
NO20091703L (no) Heterocykliske sylfonamider med EDG-I antagonistisk aktivitet
MX2009011543A (es) Metodo para la produccion de la 2,4'-dimetil-3-piperidino-propiofe nona (tolperisona), altamente pura, composiciones farmaceuticas que contienen la misma al igual que formulaciones de ingrediente activo que contienen la tolperisona.
MX2011010732A (es) Pirimidinas sustituidas por imidazol utiles en el tratamiento de trastornos relacionados con glucogeno sintasa cinasa 3 como la enfermedad de alzheimer.

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees